MTOR and cancer: Moreover, the availability of CDX-3379, the first HER3 blocking antibody that recognizes both human and mouse HER326 enabled us to investigate the direct impact of blocking HER3-PI3K/mTOR signaling in cancer cells on their TIME in syngeneic animal models.